Pharmacological inhibition of the activation of the JAK/STAT3 pathway has been shown to reduce serum urate levels and delay the progression of kidney fibrosis and CKD in adenine- and PO-induced hyperuricemia mouse models (Pan et al., 2021b). This evidence concerns the gene STAT3 and chronic kidney disease.